---
title: "Starcoin Secures Injunction as HKEX Panel Upholds Trading Suspension Decision"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284509437.md"
description: "Starcoin Group Limited's trading suspension by the Hong Kong Stock Exchange has been upheld due to insufficient operations and assets. The company has secured an interim injunction to block the suspension and plans to seek judicial review. This situation raises concerns for shareholders and highlights increased regulatory scrutiny of underperforming companies in Hong Kong. Trading remains active as the legal process unfolds, with the company's market cap at HK$361.1M and a strong sell sentiment in the market."
datetime: "2026-04-29T05:08:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284509437.md)
  - [en](https://longbridge.com/en/news/284509437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284509437.md)
---

# Starcoin Secures Injunction as HKEX Panel Upholds Trading Suspension Decision

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).

Starcoin Group Limited has disclosed that the Listing Review Committee of the Hong Kong Stock Exchange upheld an earlier decision to suspend trading in its shares, citing the company’s failure to maintain sufficient operations and assets to justify continued listing. The ruling follows a series of reviews under Listing Rule 13.24 and leaves the group’s listing status under significant pressure, raising concerns for shareholders about the company’s operational scale and compliance profile.

In response, Starcoin has obtained an interim injunction that temporarily blocks implementation of the suspension decision and plans to formally apply for leave to seek judicial review, alongside a request for further interim relief. Trading in the company’s shares remains active pending the court process, but the dispute injects legal and regulatory uncertainty into the stock and underscores heightened oversight of underperforming issuers on the Hong Kong market.

**More about Innovative Pharmaceutical Biotech**

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda with limited liability. The group is listed on the Main Board of the Hong Kong Stock Exchange under stock code 399, and its operations have recently come under regulatory scrutiny over the sufficiency of its business activities and asset base.

**Average Trading Volume:** 47,608,708

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$361.1M

### Related Stocks

- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [00399.HK](https://longbridge.com/en/quote/00399.HK.md)

## Related News & Research

- [HKEX Sets Out Board Composition and Committee Structure](https://longbridge.com/en/news/284569002.md)
- [Extransfer Seeks Hong Kong IPO As Accounting Losses Hide A Cash Cow](https://longbridge.com/en/news/284565367.md)
- [Malaysia, Hong Kong bourse operators to offer cross-border investment opportunities](https://longbridge.com/en/news/280771866.md)
- [Can Hong Kong’s listing reform 2.0 win over innovative firms?](https://longbridge.com/en/news/282404036.md)
- [HKEX proposes halving settlement cycle to boost Hong Kong’s financial profile](https://longbridge.com/en/news/283162462.md)